Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Aberdeen Group plc
Aberdeen Group plc significantly reduced its stake in Ionis Pharmaceuticals ($IONS) by 78.4% in the third quarter, selling 318,770 shares and retaining 87,924 shares valued at $5.75 million. This comes amidst substantial insider selling, with CEO Brett Monia and EVP Eric Swayze selling shares totaling approximately $7 million, contributing to insiders selling 481,356 shares worth about $38.99 million in the last 90 days. Despite this selling activity, analysts maintain a "Moderate Buy" consensus rating with an average price target of $86.95, and several firms have recently raised their price targets for the stock.
Ionis Ends Early-Stage Hero Study in Down Syndrome Alzheimer’s Risk: What Investors Should Know
Ionis Pharmaceuticals Inc. (IONS) has terminated its early-stage "Hero" study, which investigated the safety and pharmacokinetics of ION269 for Down syndrome patients at risk of Alzheimer’s disease. The trial was a Phase 1b study designed to assess a single dose of the experimental drug delivered into the spinal fluid. While a setback for Ionis's Alzheimer's endeavors in this specific demographic, the company's broader RNA-based pipeline remains a focus, and investors will be looking for reasons behind the termination and its implications for Ionis's market positioning.
Ionis updates time for fourth quarter and full year 2025 financial results webcast
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has announced a change in the start time for its fourth quarter and full year 2025 financial results webcast. The webcast, originally scheduled for 11:30 a.m. Eastern Time on Wednesday, February 25, will now take place at 8:30 a.m. Eastern Time on the same day. The date of the call remains unchanged, and the webcast can be accessed via the company's investor relations website.
Ionis updates time for fourth quarter and full year 2025 financial results webcast
Ionis Pharmaceuticals, Inc. announced a change in the start time for its fourth quarter and full year 2025 financial results webcast. Originally scheduled for 11:30 a.m. Eastern Time, the webcast will now be held at 8:30 a.m. Eastern Time on Wednesday, February 28, 2026. The date of the call remains unchanged, and a replay will be available for a limited time at the same web address.
Insiders At Ionis Pharmaceuticals Sold US$8.8m In Stock, Alluding To Potential Weakness
Insiders at Ionis Pharmaceuticals (NASDAQ:IONS) have sold a significant amount of stock, totaling US$8.8 million in the last three months and a substantial stake over the last year, primarily by Founder Brett Monia. While insider selling doesn't always signal trouble, the volume of sales by multiple insiders suggests potential weakness. Despite high insider ownership (0.8% of the company), the consistent selling warrants caution from investors.
Transthyretin Amyloid Cardiomyopathy Market Set for Explosive Growth to US$ 64.09 Billion by 2033, Led by North America | Key Players - Pfizer Inc., Ionis Pharmaceuticals, Inc
The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market, valued at US$ 4.32 Billion in 2024, is projected to reach US$ 64.09 Billion by 2033, growing at a CAGR of 35.3%. This explosive growth is driven by increasing disease awareness, improved diagnostics, an aging population, and advancements in targeted therapies like TTR stabilizers and RNAi therapies. North America leads the market, with key players including Pfizer Inc. (78% market share) and Alnylam Pharmaceuticals, Inc. (21% market share).
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Eric Swayze Sells 15,642 Shares
Ionis Pharmaceuticals' EVP Eric Swayze sold 15,642 shares for approximately $1.28 million on February 13, 2026, reducing his direct ownership by 32.76%. This sale is part of a larger trend of insider sell-offs by Swayze, totaling 55,217 shares since January 2, 2026, for about $4.4 million. The company's stock traded down 1.4% to $80.60, with analysts holding a "Moderate Buy" rating and a consensus price target of $86.95.
Responsive Playbooks and the IONS Inflection
This article analyzes Ionis Pharmaceuticals Inc. (NASDAQ: IONS), highlighting a potential inflection point despite weak near-term sentiment. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal insights, suggesting strong mid and long-term outlooks for IONS.
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) Director Sells 5,000 Shares of Stock
Ionis Pharmaceuticals (NASDAQ:IONS) Director B Lynne Parshall sold 5,000 shares of the company's stock on February 11th, reducing her stake by 8.15%. The transaction totaled $413,600, with shares sold at an average price of $82.72. Following the sale, Parshall directly owns 56,344 shares.
Insider Sell: B Parshall Sells 5,000 Shares of Ionis Pharmaceuti
B Parshall, a Director at Ionis Pharmaceuticals Inc (IONS), sold 5,000 shares of the company, reducing his holdings to 56,344 shares. This transaction is part of a larger trend for Parshall, who has sold 35,000 shares over the past year without any purchases. The stock was trading at $82.72, and with a GF Value of $46.55, it is considered significantly overvalued.
Severe Hypertriglyceridemia Market: High-Growth Opportunities for Investors to 2034 - DelveInsight
DelveInsight projects the Severe Hypertriglyceridemia (SHTG) market to reach approximately USD 2,421 million in 2023, with significant growth anticipated through 2034. The report highlights emerging therapies like Tryngolza by Ionis and plozasiran by Arrowhead Pharmaceuticals, and notes that the United States currently holds the largest market share. The increasing prevalence of metabolic disorders and the associated risk of acute pancreatitis are key market drivers, while the high cost of novel therapies and strict regulatory hurdles present challenges.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Ionis Pharmaceuticals (NASDAQ:IONS) has received a "Moderate Buy" consensus rating from twenty-one brokerages, with an average 12-month price target of $86.95. Several analysts recently raised their price targets, and Barclays initiated coverage with an "overweight" rating. Despite significant insider selling over the past 90 days, institutional investors own a substantial 93.9% of the company's stock.
Ionis Pharmaceuticals (IONS) Projected to Post Quarterly Earnings on Wednesday
Ionis Pharmaceuticals (NASDAQ: IONS) is projected to announce its Q4 2025 earnings before market open on Wednesday, February 18, 2026, with analysts expecting a loss of ($1.23) per share. The company currently has a "Moderate Buy" consensus rating and an average price target of $86.95 from analysts. Insider selling has been noted, with executives disposing of a significant number of shares recently, although institutional investors hold a large portion of the stock.
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Ionis Pharmaceuticals (IONS) is anticipated to surpass its Q4 earnings estimates, despite Zacks projecting a year-over-year decline in earnings and revenue. The company's Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +17.84% and a Zacks Rank #2, which together strongly suggest an earnings beat. Furthermore, Ionis Pharmaceuticals has a history of consistently beating consensus EPS estimates over the last four quarters.
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Ionis Pharmaceuticals (IONS) is expected to outperform its Q4 earnings estimates, with analysts revising their EPS forecast upward. The company's strong Zacks Rank of #2 and a positive Earnings ESP of +17.84% suggest a high probability of an earnings beat. This positive outlook follows Ionis Pharmaceuticals consistently beating consensus EPS estimates in the last four quarters.
Ionis to hold fourth quarter and full year 2025 financial results webcast
Ionis Pharmaceuticals, Inc. announced it will host a live webcast on Wednesday, February 25, 2026, at 11:30 a.m. Eastern Time. The webcast will discuss the company's fourth quarter and full year 2025 financial results and program advancements. Ionis is known for inventing medicines for serious diseases, with a pipeline in neurology, cardiometabolic disease, and other areas of high patient need.
Ionis to hold fourth quarter and full year 2025 financial results webcast
Ionis Pharmaceuticals, Inc. announced it will host a live webcast on Wednesday, February 25, 2026, at 11:30 a.m. Eastern Time. The webcast will cover its fourth-quarter and full-year 2025 financial results and highlight progress on key programs. A replay will be available on the company's investor relations website.
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Ionis Pharmaceuticals (IONS) is expected to outperform its earnings estimates for Q4 2025, according to Zacks Equity Research. The company is predicted to report a year-over-year decline in both earnings and revenue, but a positive Earnings ESP combined with a Zacks Rank of #2 suggests a high probability of an EPS beat. This outlook is based on recent bullish revisions by analysts.
Ionis Pharma CEO Monia sells $2.52m in shares
Ionis Pharmaceuticals CEO Brett P. Monia sold 29,430 shares of the company's common stock for $2.52 million. This transaction occurred when Ionis stock was trading near its 52-week high, having delivered a significant return over the past year. The company is set to report earnings soon, and recent developments include European Commission approval for Dawnzera and positive Phase 3 trial results for bepirovirsen.
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia Sells 29,430 Shares
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia sold 29,430 shares of the company's stock on February 6th, reducing his stake by 10.37%. The sale was valued at approximately $2.525 million, with shares sold at an average price of $85.79. Following the transaction, Monia now owns 254,497 shares worth roughly $21.83 million, while the company's stock currently trades around $84.29 with analysts maintaining a "Moderate Buy" consensus rating and an average target price of $86.95.
Ionis Pharmaceuticals (IONS) Valuation Check As Dawnzera Approval And Other Milestones Support Growth Prospects
Ionis Pharmaceuticals (IONS) is under valuation scrutiny following key drug pipeline milestones, including European approval for Dawnzera and FDA Breakthrough Therapy status for zilganersen, which have contributed to significant share price returns. Despite a narrative suggesting a fair value slightly above its current price and a large intrinsic discount according to a DCF model, the market is already applying a high P/S ratio compared to industry peers, indicating demanding expectations for future execution. Investors are encouraged to consider these factors alongside potential regulatory delays or pricing challenges.
Candriam S.C.A. Has $39.99 Million Stock Position in Ionis Pharmaceuticals, Inc. $IONS
Candriam S.C.A. decreased its stake in Ionis Pharmaceuticals (NASDAQ:IONS) by 15.7% during the third quarter, reducing its holdings to 611,237 shares valued at $39.99 million. This adjustment comes amidst significant insider selling, totaling $34.77 million over the past three months, and a "Moderate Buy" consensus from Wall Street analysts with an average price target of $86.95. The stock has seen a 12-month low of $23.95 and a high of $86.74, currently trading near its 52-week high.
Wealth Enhancement Advisory Services LLC Sells 15,476 Shares of Ionis Pharmaceuticals, Inc. $IONS
Wealth Enhancement Advisory Services LLC reduced its stake in Ionis Pharmaceuticals by 67.5% in the third quarter, selling 15,476 shares, though still holding 7,439 shares valued at $513,000. This comes alongside heavy insider selling totaling over $34.8 million in the past 90 days. Despite this, analysts maintain a "Moderate Buy" consensus with an average target price of $86.95, and several firms have raised their price objectives for the stock.
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 6 Analysts
Six analysts have recently provided ratings for Ionis Pharmaceuticals (NASDAQ: IONS), with a majority holding bullish or somewhat bullish sentiments. The average 12-month price target increased to $98.17, up 15.05% from the previous average, with a high estimate of $110.00 and a low of $87.00. The company shows positive revenue growth and strong net margin, but faces challenges with debt management and returns on equity and assets below industry averages.
C WorldWide Group Holding A S Sells 24,000 Shares of Ionis Pharmaceuticals, Inc. $IONS
C WorldWide Group Holding A S reduced its stake in Ionis Pharmaceuticals by 5.3% in Q3 2025, selling 24,000 shares but still owning 426,000 shares valued at $27.87 million. Company insiders, including CEO Brett P. Monia and EVP Eric Swayze, also sold a significant number of shares recently. Analysts maintain a "Moderate Buy" rating for Ionis Pharmaceuticals with an average target price of $86.45.
Ionis Pharmaceuticals stock hits 52-week high at 86.31 USD By Investing.com
Ionis Pharmaceuticals (IONS) stock reached a 52-week high of $86.31 USD, reflecting strong investor confidence with a 156.23% increase over the past year. This surge is supported by recent European approval for Dawnzera, positive Phase 3 trial results for a hepatitis B drug, and Breakthrough Therapy designation for zilganersen, alongside increased price targets from RBC Capital and TD Cowen. Despite some analyst opinions suggesting potential overvaluation, the company maintains healthy liquidity and moderate debt levels.
Ionis Regulatory Wins Highlight Growing Rare Disease Revenue Potential
Ionis Pharmaceuticals has achieved significant regulatory successes, including European Commission approval for Dawnzera to prevent hereditary angioedema attacks, US FDA Breakthrough Therapy designation for zilganersen for Alexander disease, and positive Phase 3 results for bepirovirsen partnered with GSK. These milestones underscore Ionis's strategy of converting its RNA platform into commercially viable products across various disease areas and transitioning from an R&D-heavy model to a broader commercial-stage business. The article highlights the importance for investors to monitor the progression of these programs to market, considering both the revenue potential and associated risks.
Ionis Pharmaceuticals stock hits 52-week high at 86.31 USD
Ionis Pharmaceuticals (IONS) stock reached a 52-week high of $86.31, reflecting strong investor confidence and a 156.23% increase over the past year. The company has recently achieved key milestones including European approval for Dawnzera, successful Phase 3 trials for a hepatitis B drug, and FDA Breakthrough Therapy designation for zilganersen, all contributing to its growth and innovation in the pharmaceutical industry. Analysts have mixed price targets but acknowledge the company's healthy liquidity and moderate debt.
Ionis Pharmaceuticals stock hits 52-week high at 86.31 USD By Investing.com
Ionis Pharmaceuticals (IONS) stock reached a 52-week high of $86.31, reflecting strong investor confidence and a significant 156.23% increase over the past year. The company's recent achievements include the European Commission's approval of Dawnzera, positive Phase 3 trial outcomes for a hepatitis B drug partnered with GSK, and FDA Breakthrough Therapy designation for zilganersen, all contributing to its robust market performance and growth prospects. Analyst price targets vary, and while InvestingPro analysis suggests potential overvaluation, the company maintains healthy liquidity.
Ionis Pharma EVP Baroldi sells $439k in shares
Joseph Baroldi, EVP and Chief Business Officer at Ionis Pharmaceuticals (NASDAQ:IONS), sold 5,296 shares of common stock for $439,364 on January 30, 2026. This transaction follows his acquisition of 10,278 shares through vesting of restricted stock units. Despite the stock's strong annual performance, InvestingPro analysts suggest Ionis may be overvalued and predict no profitability this year, with earnings slated for February 25.
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: A Promising 9.68% Upside in the Biotech Arena
Ionis Pharmaceuticals (IONS) is a biotechnology company with a strong pipeline of RNA-targeted medicines and strategic partnerships, offering a potential 9.68% upside for investors. Despite current negative EPS and return on equity, its impressive revenue growth, favorable analyst sentiment, and position above key moving averages suggest a positive long-term outlook. Investors should consider the inherent risks of the biotech sector alongside the potential for significant growth driven by clinical trial outcomes and regulatory approvals.
Eric Swayze Sells 6,179 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
Eric Swayze, EVP of Ionis Pharmaceuticals (NASDAQ:IONS), sold 6,179 shares valued at approximately $512,424 on January 30th, reducing his position by 11.46%. Following this sale, he now holds 47,747 shares worth about $3.96 million. The stock is currently trading near its 52-week high, with a "Moderate Buy" analyst consensus and a target price of $86.45.
Ionis Pharma CFO Hougen sells $581k in shares By Investing.com
Ionis Pharmaceuticals' CFO, Elizabeth L. Hougen, sold 6,988 shares of common stock for approximately $581,702 on January 30, 2026. This transaction occurred shortly after she acquired 13,562 shares through restricted stock unit vesting on January 29, 2026. The company, valued at $13.45 billion, has seen significant stock gains despite not being profitable in the past year, while also announcing key regulatory approvals and positive clinical trial results for its drugs, prompting optimistic price targets from analysts.
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) CEO Sells 62,970 Shares of Stock
Ionis Pharmaceuticals CEO Brett Monia sold 62,970 shares of the company's stock for over $5.2 million, reducing his ownership by 18.15%. Despite this insider selling, the stock maintains a "Moderate Buy" consensus rating from analysts with an average target price of $86.45, and institutional investors hold a significant 93.86% of the company. The company's stock was trading up 0.5% during midday, with a market capitalization of $13.45 billion.
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Elizabeth Hougen Sells 6,988 Shares
Ionis Pharmaceuticals EVP Elizabeth Hougen sold 6,988 shares of the company's stock for over $581,000 on January 30th, reducing her ownership by 5%. The shares traded at $83.07, and institutional investors hold 93.86% of the stock. Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $86.45, reflecting positive sentiment.
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 5,885 Shares of Stock
Ionis Pharmaceuticals (NASDAQ:IONS) EVP C. Frank Bennett sold 5,885 shares of the company's stock on January 30th at an average price of $82.95, totaling $488,160.75. This transaction reduced his stake by 5.54%, leaving him with 100,293 shares. Coupled with a previous sale on January 16th, his total January sales amount to approximately $1.16 million, indicating significant insider selling activity.
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 6,179 Shares
Ionis Pharmaceuticals (NASDAQ:IONS) Executive Vice President Patrick O'Neil sold 6,179 shares of the company's stock on January 30th for a total value of $516,131.87. This transaction reduced his position by 7.91%. Following the sale, O'Neil now owns 71,983 shares valued at over $6 million.
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Eugene Schneider Sells 6,179 Shares
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Eugene Schneider recently sold 6,179 shares of the company's stock on January 30th for approximately $515,637. This transaction reduced his direct ownership by 8.14% to 69,702 shares. This follows another sale of 9,302 shares on January 16th.
Ionis Pharma EVP Baroldi sells $439k in shares
Joseph Baroldi, EVP of Ionis Pharmaceuticals, sold 5,296 shares for $439,364 and also acquired 10,278 shares through vesting of restricted stock units. The company has seen significant recent developments, including EU approval for Dawnzera, positive Phase 3 results for bepirovirsen, and FDA Breakthrough Therapy designation for zilganersen. Analysts have raised price targets for Ionis, highlighting its transition to a commercial entity and expected growth.
Barclays’ Supportive View on Ionis’s RNA Pipeline and Partnerships Might Change The Case For Investing In Ionis Pharmaceuticals (IONS)
Barclays analyst Eliana Merle initiated coverage on Ionis Pharmaceuticals with a positive rating, highlighting its RNA-targeted therapy pipeline and collaborations, particularly with late-stage candidates Olezarsen and Donidalorsen. This positive analyst attention reinforces confidence in Ionis's future, despite existing valuation concerns, ongoing losses, and legal risks. The company's investment narrative centers on its RNA platform and potential launches justifying its current valuation, while fair value estimates from the Simply Wall St Community show a wide range, underscoring the need for diverse perspectives.
Privium Fund Management B.V. Sells 18,700 Shares of Ionis Pharmaceuticals, Inc. $IONS
Privium Fund Management B.V. reduced its stake in Ionis Pharmaceuticals by 7.0%, selling 18,700 shares and now owning 248,894 shares valued at $16.28 million. Insider activity shows significant selling, with executives disposing of a total of 277,891 shares worth $21.73 million in the past 90 days. Despite insider selling, analyst sentiment remains largely positive, with a consensus "Moderate Buy" rating and an average price target of $86.45, while the stock currently trades around $82.67.
Lisanti Capital Growth LLC Acquires Shares of 92,124 Ionis Pharmaceuticals, Inc. $IONS
Lisanti Capital Growth LLC recently acquired 92,124 shares of Ionis Pharmaceuticals (NASDAQ:IONS) for approximately $6.03 million, making it their 18th-largest holding. Institutional investors collectively own about 93.86% of Ionis stock, with several firms increasing their stakes. Despite recent analyst upgrades and a "Moderate Buy" consensus rating with an average target price of $86.45, company insiders have sold a significant number of shares totaling around $21.7 million in the past 90 days.
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Exploring a 12.94% Potential Upside Amidst Robust Pipeline
Ionis Pharmaceuticals (IONS) is a commercial-stage biotechnology company with a strong pipeline of RNA-targeted therapies, holding a significant market presence and a market cap of $13 billion. Despite negative EPS and ROE, the company shows promising revenue growth (17.10%) and strategic collaborations. Analysts are optimistic, with 16 buy ratings and an average target price suggesting a 12.94% upside, supported by solid technical indicators.
Sovran Advisors LLC Lowers Stake in Ionis Pharmaceuticals, Inc. $IONS
Sovran Advisors LLC significantly reduced its holdings in Ionis Pharmaceuticals (NASDAQ:IONS) by 53.1% in the third quarter, selling over 171,000 shares. Despite this, other institutional investors increased their stakes, and Ionis Pharmaceuticals posted better-than-expected earnings and received EU approval for Dawnzera. However, a series of insider share sales by numerous senior staff members were also reported, which could signal reduced insider confidence or profit-taking.
Ionis Pharmaceuticals, Inc. $IONS Position Reduced by Sector Gamma AS
Sector Gamma AS reduced its stake in Ionis Pharmaceuticals by 5.2% in Q3, now owning 270,963 shares valued at approximately $17.7 million, making it their sixth-largest holding. Despite this reduction and recent insider selling totaling $30.5 million, the company has positive catalysts including EU approval for Dawnzera and multiple analysts raising price targets, leading to a consensus "Moderate Buy" rating. The stock's performance has seen fluctuations, but institutional ownership remains high at 93.86%.
BLB&B Advisors LLC Has $7.76 Million Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS
BLB&B Advisors LLC reduced its stake in Ionis Pharmaceuticals by 21.7%, now holding 118,600 shares valued at $7.76 million, while other institutional investors like Adage Capital significantly increased their holdings. Insider selling has been notable, with CEO Brett Monia and a director offloading shares, contributing to over $30 million in insider sales. Despite insider selling, analyst sentiment for Ionis Pharmaceuticals remains positive, with a "Moderate Buy" consensus and an average price target of $86.45, further bolstered by the recent EU approval of Dawnzera.
Why Ionis Pharmaceuticals (IONS) Is Up 5.2% After EU Approval of DAWNZERA for HAE Prevention
Ionis Pharmaceuticals (IONS) saw its stock rise by 5.2% following the European Commission's approval of DAWNZERA™ (donidalorsen) for preventing hereditary angioedema (HAE) attacks. This approval expands Ionis's commercial reach in Europe, validating its RNA-targeted antisense technology and adding new revenue streams. While DAWNZERA's European approval is a positive development, the article notes that its immediate financial impact is incremental, and the company still faces significant execution risks and a premium valuation.
Teacher Retirement System of Texas Sells 194,328 Shares of Ionis Pharmaceuticals, Inc. $IONS
The Teacher Retirement System of Texas significantly reduced its stake in Ionis Pharmaceuticals (NASDAQ:IONS) by selling 194,328 shares, cutting its holdings by 29.1%. This divestment occurred alongside substantial insider selling by company executives, totaling over $30.5 million in shares over the past 90 days. Despite these sales, analysts maintain a "Moderate Buy" rating for Ionis, with a consensus target price of $86.45, as the company recently surpassed revenue estimates and received EU approval for its drug Dawnzera.
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 3,977 Shares of Stock
Ionis Pharmaceuticals' EVP Shannon Devers sold 3,977 shares of the company's stock for over $323,000, reducing her stake by 15%. This sale, along with other significant insider sales on the same day, is noted by market commentators as potential profit-taking that could pressure the stock, despite a recent EU approval for one of Ionis' drugs and some analysts upgrading price targets. The stock trades near $80 with a "Moderate Buy" consensus rating and an average target price of $86.45.
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Shows High-Quality Technical Breakout Setup
Ionis Pharmaceuticals Inc (NASDAQ:IONS) has been identified through a technical breakout screen as a promising stock. It boasts a strong ChartMill Technical Rating of 9 out of 10, indicating excellent technical health with a clear long-term positive trend and exceptional relative strength against the market and its industry peers. The stock also has a Setup Quality Rating of 9 out of 10, showing a constructive consolidation pattern that suggests a potential breakout, making it an attractive prospect for technical investors.
